Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease

BackgroundThe levodopa challenge test is routinely used in Parkinson disease (PD) to determine a patient’s motor improvement following levodopa administration [levodopa response (LR)]. LR is most commonly reported as a percent OFF to ON change in the Unified Parkinson Disease Rating Scale (UPDRS) pa...

Full description

Bibliographic Details
Main Authors: Marcus Pieterman, Scott Adams, Mandar Jog
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Neurology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fneur.2018.00260/full
id doaj-936087a8290642afb3812f156e8aea6f
record_format Article
spelling doaj-936087a8290642afb3812f156e8aea6f2020-11-24T23:02:55ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-05-01910.3389/fneur.2018.00260355629Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson DiseaseMarcus Pieterman0Scott Adams1Scott Adams2Mandar Jog3Department of Clinical Neurological Sciences, Schulich School of Medicine & Dentistry, University of Western Ontario, CanadaSchool of Communication Sciences and Disorders, University of Western Ontario, CanadaDepartment of Clinical Neurological Sciences, Schulich School of Medicine & Dentistry, University of Western Ontario, CanadaDepartment of Clinical Neurological Sciences, Schulich School of Medicine & Dentistry, University of Western Ontario, CanadaBackgroundThe levodopa challenge test is routinely used in Parkinson disease (PD) to determine a patient’s motor improvement following levodopa administration [levodopa response (LR)]. LR is most commonly reported as a percent OFF to ON change in the Unified Parkinson Disease Rating Scale (UPDRS) part III score, and occasionally as an absolute difference in score. This inconsistency in LR determination alters how clinical factors such as patient age and disease duration are understood in relation to LR in PD.ObjectiveThe aim of this study was to compare the calculation of the LR as either a percent change or difference in UPDRS-III motor score between OFF and ON medication. These two scores were then used to correlate to disease duration, patient age, levodopa duration, levodopa equivalent dose (LED), OFF score, cognition, mood, gait, and quality of life (QOL).Methods70 PD patients underwent the levodopa challenge test. The UPDRS-III motor examination was performed in the defined OFF and ON medication states to determine LR. Each patient was assessed after 12–14 h without anti-parkinsonian medication and then given three 100/25 mg levodopa/carbidopa tablets. LR was reported as both a difference in score [OFF − ON; absolute LR (aLR)] and as a percent change in score [(OFF − ON)/OFF*100%; %LR]. Patients completed the following non-motor symptom assessment scales: Montreal Cognitive Assessment, Freezing of Gait Questionnaire, Activities-specific Balance Confidence Scale, Parkinson’s Disease Questionnaire, and Geriatric Depression Scale. The effect of the LR calculation method was correlated to the clinical measures.ResultsThe aLR was significantly associated with disease duration (r = 0.40), levodopa duration (r = 0.47), OFF motor score (r = 0.58), and LED (r = 0.31), but not age. The aLR was also found to have a significant relationship with clinical scales assessing cognition (r = 0.41), freezing of gait (r = 0.35), QOL (r = 0.40), and depression (r = 0.30). By contrast, the more commonly used %LR demonstrated no significant relationships with any of the variables tested.ConclusionAlthough the %LR is more commonly employed in clinical protocols and research studies, the aLR is the superior method for reporting motor response to levodopa in PD given its significant associations with the clinical factors evaluated.http://journal.frontiersin.org/article/10.3389/fneur.2018.00260/fullParkinson diseaselevodopalevodopa responselevodopa challenge testUnified Parkinson Disease Rating Scaledisease duration
collection DOAJ
language English
format Article
sources DOAJ
author Marcus Pieterman
Scott Adams
Scott Adams
Mandar Jog
spellingShingle Marcus Pieterman
Scott Adams
Scott Adams
Mandar Jog
Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
Frontiers in Neurology
Parkinson disease
levodopa
levodopa response
levodopa challenge test
Unified Parkinson Disease Rating Scale
disease duration
author_facet Marcus Pieterman
Scott Adams
Scott Adams
Mandar Jog
author_sort Marcus Pieterman
title Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
title_short Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
title_full Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
title_fullStr Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
title_full_unstemmed Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
title_sort method of levodopa response calculation determines strength of association with clinical factors in parkinson disease
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2018-05-01
description BackgroundThe levodopa challenge test is routinely used in Parkinson disease (PD) to determine a patient’s motor improvement following levodopa administration [levodopa response (LR)]. LR is most commonly reported as a percent OFF to ON change in the Unified Parkinson Disease Rating Scale (UPDRS) part III score, and occasionally as an absolute difference in score. This inconsistency in LR determination alters how clinical factors such as patient age and disease duration are understood in relation to LR in PD.ObjectiveThe aim of this study was to compare the calculation of the LR as either a percent change or difference in UPDRS-III motor score between OFF and ON medication. These two scores were then used to correlate to disease duration, patient age, levodopa duration, levodopa equivalent dose (LED), OFF score, cognition, mood, gait, and quality of life (QOL).Methods70 PD patients underwent the levodopa challenge test. The UPDRS-III motor examination was performed in the defined OFF and ON medication states to determine LR. Each patient was assessed after 12–14 h without anti-parkinsonian medication and then given three 100/25 mg levodopa/carbidopa tablets. LR was reported as both a difference in score [OFF − ON; absolute LR (aLR)] and as a percent change in score [(OFF − ON)/OFF*100%; %LR]. Patients completed the following non-motor symptom assessment scales: Montreal Cognitive Assessment, Freezing of Gait Questionnaire, Activities-specific Balance Confidence Scale, Parkinson’s Disease Questionnaire, and Geriatric Depression Scale. The effect of the LR calculation method was correlated to the clinical measures.ResultsThe aLR was significantly associated with disease duration (r = 0.40), levodopa duration (r = 0.47), OFF motor score (r = 0.58), and LED (r = 0.31), but not age. The aLR was also found to have a significant relationship with clinical scales assessing cognition (r = 0.41), freezing of gait (r = 0.35), QOL (r = 0.40), and depression (r = 0.30). By contrast, the more commonly used %LR demonstrated no significant relationships with any of the variables tested.ConclusionAlthough the %LR is more commonly employed in clinical protocols and research studies, the aLR is the superior method for reporting motor response to levodopa in PD given its significant associations with the clinical factors evaluated.
topic Parkinson disease
levodopa
levodopa response
levodopa challenge test
Unified Parkinson Disease Rating Scale
disease duration
url http://journal.frontiersin.org/article/10.3389/fneur.2018.00260/full
work_keys_str_mv AT marcuspieterman methodoflevodoparesponsecalculationdeterminesstrengthofassociationwithclinicalfactorsinparkinsondisease
AT scottadams methodoflevodoparesponsecalculationdeterminesstrengthofassociationwithclinicalfactorsinparkinsondisease
AT scottadams methodoflevodoparesponsecalculationdeterminesstrengthofassociationwithclinicalfactorsinparkinsondisease
AT mandarjog methodoflevodoparesponsecalculationdeterminesstrengthofassociationwithclinicalfactorsinparkinsondisease
_version_ 1725634674719457280